Journal of Clinical Oncology
Articles in this Issue
Detecting <i>MTAP</i> loss in liquid biopsies from patients (pts) with clinically advanced urothelial bladder cancer (CAUBC).
819 Background: MTAP loss is an emerging biomarker guiding investigational assessment of protein argin...
Interim analysis of vorolanib combined with cadonilimab in previously untreated patients with advanced renal cell carcinoma.
499 Background: Targeted therapy combined with immunotherapy is the first-line standard for advanced renal cell carcinoma...
Real-world overall survival (OS) improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras.
686 Background: Over the past 3 decades, treatment of mUC has been transformed by 3 landmark backbone therapies: platinum-...
A prospective, randomized, cross-over trial to assess patient preference for goserelin microsphere versus goserelin implant in prostate cancer: Interim results of the GOMIMP study.
130 Background: Androgen deprivation therapy (ADT), particularly gonadotropin-releasing hormone (GnRH) agonists like goser...
Correlation of mutated <i>B2M</i> , an immune-related gene, with overall survival in renal cell carcinoma.
555 Background: Renal cell carcinoma (RCC) is the most common renal malignancy and although most cases are sporadic, certa...
TRIM28-mediated SUMOylation of ERG at K389 and its association with cell proliferation, PARP inhibitor response, and 53BP1 expression in castration-resistant prostate cancer.
234 Background: Prostate cancer (PCa) patients with homologous recombination repair (HRR) gene mutations often show sensit...
High-risk localized prostate cancer treated with neoadjuvant LHRH agonist/antagonist and enzalutamide plus the glucocorticoid receptor antagonist relacorilant versus placebo.
TPS415 Background: Of the estimated 31,000 high risk localized prostate cancer (PC) cases in 2025, up to 46% have a risk o...
A phase III randomised control clinical trial of radiotherapy with radiosensitisation versus intravesical bacillus Calmette-Guerin therapy for high-risk non-muscle invasive bladder cancer: TRAIN.
TPS880 Background: High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) is typically treated with surgery (TURBT; Trans...
Impact of bleomycin shortage on real-world outcomes in germ cell tumors: A multicenter retrospective analysis in Brazil.
600 Background: Male germ cell tumors are rare malignancies, accounting for approximately 5% of all male cancers and predo...
A phase 1/2 study to assess peptidomimetic carbonic anhydrase IX imaging and therapy with [ <sup>68</sup> Ga]Ga-DPI-4452 and [ <sup>177</sup> Lu]Lu-DPI-4452 in patients with advanced clear cell renal cell carcinoma and other solid tumors.
TPS569 Background: The diagnostic and clinical benefit of the peptidomimetic carbonic anhydrase IX (CA IX) -binding theran...
The prognostic role of PD-L1 in penile squamous cell carcinoma: A systematic review and meta-analysis.
13 Background: Penile squamous cell carcinoma (PSCC) is a rare tumor with limited therapeutic options in advanced disease....
The LuxAR-02 phase II study of luxdegalutamide in combination with [ <sup>177</sup> Lu]Lu-PSMA-617 in patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration resistant prostate cancer (mCRPC).
TPS278 Background: Patients with mCRPC have a poor prognosis and often experience rapid disease progression with current s...
Real-world ARPI utilization patterns and outcomes in metastatic castration-sensitive prostate cancer.
119 Background: Intensification of androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs) or...
Direct comparative and network meta analysis of PARP inhibitor and androgen receptor targeted therapies in first line mCRPC: Defining the optimal regimen among 8,997 patients.
201 Background: Metastatic castration resistant prostate cancer remains a lethal stage despite major therapeutic advances....
Treatment interruption guided by on-treatment prostate-specific membrane antigen (PSMA) PET/CT imaging in metastatic hormone-sensitive prostate cancer (mHSPC).
22 Background: PSMA PET/CT (PET) imaging is approved for staging high-risk prostate cancer (PCa) and for suspected PCa rec...
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
LBA630 Background: Enfortumab vedotin (EV) + pembrolizumab (pembro) is the established first-line standard of care for loc...
Real-world effectiveness of systemic therapies after [ <sup>177</sup> Lu]Lu-PSMA-617 ( <sup>177</sup> Lu-PSMA-617) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC): A prostate cancer disease observation (PRECISION) data platform analysis.
79 Background: In March 2025, the indication for 177 Lu-PSMA-617 was expanded to i...
Sarcomatoid versus rhabdoid dedifferentiation and histologic grade-specific outcomes in metastatic clear cell renal cell carcinoma (mccRCC): A multi-institutional analysis of 514 patients.
456 Background: WHO/ISUP grade 4 RCC, defined by rhabdoid or sarcomatoid dedifferentiation or extreme nuclear pleomorphism...
Fifteen-year survival analysis from the ASCENDE-RT randomized trial of external beam boost versus brachytherapy boost in localized prostate cancer.
306 Background: Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (ASCENDE-RT) trial...
Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.
739 Background: Ave 1LM is a recommended treatment option for patients (pts) with aUC without progression after 1L platinu...
Comparative outcomes of RANKL inhibitors versus bisphosphonates in metastatic prostate cancer with bone metastases: A TriNetX real-world analysis.
113 Background: Skeletal-related events (SREs) such as pathologic fractures, spinal cord compression, and the need for pal...
Homologous recombination deficiency signature (HRDsig) status in <i>BRCA1/2</i> wild type ( <i>BRCA1/2</i> wt) clinically advanced prostate cancer (CAPC).
219 Background: The HRDsig biomarker has emerged as a putative predictor of PARP inhibitor (PARPi) efficacy in multiple tu...
Integrating genomic profiling and circulating tumor DNA monitoring to optimize surveillance strategies in muscle-invasive bladder cancer.
797 Background: Up to 50% of patients with muscle-invasive bladder cancer (MIBC) relapse following curative-intent therapy...
FAP+FN1+CAV1+ cancer-associated fibroblast subtype and its association with aggressive behavior in localized prostate cancer.
392 Background: Cancer-associated fibroblasts (CAFs) are a major component of the tumor microenvironment, exerting both tu...
Effect of loss of KDM6A-mediated genomic instability and metabolic reprogramming on response to therapeutic perturbations in bladder cancer.
816 Background: Mutations in genes encoding critical epigenetic regulators are frequently observed in advanced bladder can...